Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Argus Health
Accenture
Mallinckrodt
Citi
QuintilesIMS
Harvard Business School
Chinese Patent Office
Novartis

Generated: January 18, 2018

DrugPatentWatch Database Preview

Bayer Healthcare Company Profile

« Back to Dashboard

Summary for Bayer Healthcare
International Patents:225
US Patents:10
Tradenames:22
Ingredients:12
NDAs:28

Drugs and US Patents for Bayer Healthcare

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Healthcare Llc CLARITIN HIVES RELIEF REDITAB loratadine TABLET, ORALLY DISINTEGRATING;ORAL 020704-003 Nov 19, 2003 OTC Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Bayer Healthcare Llc CLARITIN HIVES RELIEF loratadine SYRUP;ORAL 020641-003 Nov 19, 2003 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Bayer Healthcare Llc SHADE UVAGUARD avobenzone; octinoxate; oxybenzone LOTION;TOPICAL 020045-001 Dec 7, 1992 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Bayer Healthcare Llc OCUCLEAR oxymetazoline hydrochloride SOLUTION/DROPS;OPHTHALMIC 018471-001 May 30, 1986 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Bayer Healthcare Llc GYNE-LOTRIMIN COMBINATION PACK clotrimazole CREAM, TABLET;TOPICAL, VAGINAL 020289-002 Apr 26, 1993 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Bayer Healthcare Llc MYCELEX-7 clotrimazole CREAM;VAGINAL 018230-002 Dec 26, 1991 OTC No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Bayer Healthcare Llc MYCELEX-7 COMBINATION PACK clotrimazole CREAM, TABLET;TOPICAL, VAGINAL 020389-002 Jun 23, 1994 OTC No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Bayer Healthcare ALIQOPA copanlisib dihydrochloride POWDER;IV (INFUSION) 209936-001 Sep 14, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Bayer Healthcare Llc GYNE-LOTRIMIN 3 clotrimazole CREAM;VAGINAL 020574-001 Nov 24, 1998 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Bayer Healthcare Llc MIRALAX polyethylene glycol 3350 FOR SOLUTION;ORAL 022015-001 Oct 6, 2006 OTC Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Bayer Healthcare

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bayer Healthcare Llc CLARITIN-D 24 HOUR loratadine; pseudoephedrine sulfate TABLET, EXTENDED RELEASE;ORAL 020470-002 Nov 27, 2002 ➤ Subscribe ➤ Subscribe
Bayer Healthcare Llc MYCELEX clotrimazole CREAM;TOPICAL 018183-001 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Bayer Healthcare Llc ZEGERID OTC omeprazole; sodium bicarbonate CAPSULE;ORAL 022281-001 Dec 1, 2009 ➤ Subscribe ➤ Subscribe
Bayer Healthcare Llc ZEGERID OTC omeprazole; sodium bicarbonate FOR SUSPENSION;ORAL 022283-001 Jun 17, 2013 ➤ Subscribe ➤ Subscribe
Bayer Healthcare Llc ZEGERID OTC omeprazole; sodium bicarbonate FOR SUSPENSION;ORAL 022283-001 Jun 17, 2013 ➤ Subscribe ➤ Subscribe
Bayer Healthcare Llc CLARITIN-D 24 HOUR loratadine; pseudoephedrine sulfate TABLET, EXTENDED RELEASE;ORAL 020470-002 Nov 27, 2002 ➤ Subscribe ➤ Subscribe
Bayer Healthcare Llc CLARITIN loratadine SYRUP;ORAL 020641-002 Nov 27, 2002 ➤ Subscribe ➤ Subscribe
Bayer Healthcare Llc SHADE UVAGUARD avobenzone; octinoxate; oxybenzone LOTION;TOPICAL 020045-001 Dec 7, 1992 ➤ Subscribe ➤ Subscribe
Bayer Healthcare Llc CLARITIN REDITABS loratadine TABLET, ORALLY DISINTEGRATING;ORAL 020704-002 Nov 27, 2002 ➤ Subscribe ➤ Subscribe
Bayer Healthcare Llc CLARITIN-D loratadine; pseudoephedrine sulfate TABLET, EXTENDED RELEASE;ORAL 019670-002 Nov 27, 2002 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for BAYER HEALTHCARE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 20 mg/1100 mg ➤ Subscribe 4/20/2010

Non-Orange Book US Patents for Bayer Healthcare

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
RE45198 Omeprazole solution and method for using same ➤ Subscribe
6,514,520 Stabilized antihistamine syrup ➤ Subscribe
6,939,550 Stabilized antihistamine syrup ➤ Subscribe
8,129,386 Fused azole-pyrimidine derivatives ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Bayer Healthcare Drugs

Supplementary Protection Certificates for Bayer Healthcare Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB01/012 United Kingdom ➤ Subscribe PRODUCT NAME: DESLORATADINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/00/157/001-013 20010115; UK EU/1/00/158/001-013 20010115; UK EU/1/00/159/001-013 20010115; UK EU/1/00/160/001-013 20010115; UK EU/1/00/161/001-013 20010115
01C/013 Belgium ➤ Subscribe PRODUCT NAME: DESLORATADINE; REGISTRTION NO/DATE: EU/1/00/160/010 20010115
C0004 France ➤ Subscribe PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730
C/GB08/005 United Kingdom ➤ Subscribe SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.
C/GB11/013 United Kingdom ➤ Subscribe PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
C/GB11/015 United Kingdom ➤ Subscribe PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Fish and Richardson
McKinsey
Argus Health
Teva
Johnson and Johnson
Dow
Cipla
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot